Immunic chief scientific officer shares insights on innovative MS therapy - ICYMI

Core Viewpoint - Immunic Inc is developing vidofludimus calcium as a treatment for multiple sclerosis (MS), with promising results from clinical trials and ongoing Phase 3 studies expected to conclude in 2026 [2][8]. Company Overview - Immunic Inc's lead asset, vidofludimus calcium, targets both relapsing and progressive forms of MS, which affects approximately 1 million people in the US and 2.8 million globally [13][12]. - The drug has a dual mode of action, providing neuroprotection, anti-inflammatory, and antiviral properties [10][14]. Clinical Trials - Phase 2 studies of vidofludimus calcium involved over 200 relapsing MS patients, showing statistically significant efficacy and a clean safety profile, leading to the initiation of Phase 3 studies [8]. - The ENSURE program consists of two parallel studies recruiting around 2,000 patients, with completion expected in 2026 [8]. - The CALLIPER study, focusing on progressive MS, has fully recruited 467 patients, with top-line data anticipated in April 2025 [16]. Disease Understanding - MS is characterized as an immune-mediated demyelinating disease, where the immune system attacks the myelin coating of nerves, leading to severe disability without effective treatment [11]. - Relapsing MS accounts for 85% of cases, with defined relapses followed by periods of remission, although ongoing worsening can occur between relapses [5][12]. Health Insights - The discussion on brain health emphasizes the importance of lifestyle choices, including exercise and nutrition, which can positively impact brain function and overall health [9][17].